Quazar Investment

Quazar Investment is a leading strategic investment firm headquartered in Abu Dhabi, UAE, managing over $3.3 billion in assets under management. Backed by key partnerships with the UAE Government, Quazar focuses on transformative investments in biotechnology, healthcare, and next-generation infrastructure across the MENA region and globally. In 2025, the firm entered into a $50 million strategic partnership with NeOnc Technologies to launch and accelerate a clinical-stage CNS platform in the Middle East. Through its majority-controlled subsidiaries, NuroMENA and NuroCure, Quazar is spearheading the clinical advancement of lead candidates NEO100 and NEO212 for the treatment of brain cancer and other CNS disorders. The firm is a key player in the UAE's strategic initiative to establish a world-class biotechnology hub and deliver groundbreaking neuro-oncology solutions.